failure is_老虎社区_美港股上老虎

不油腻的哒哒哒
2022-04-07

failure is the mother of success

Aptinyx slides as diabetic pain trial fails to reach main goal

syahrir maulana/iStock via Getty Images The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX

Aptinyx slides as diabetic pain trial fails to reach main goal

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":619521606,"tweetId":"619521606","gmtCreate":1649341811621,"gmtModify":1649341811621,"author":{"id":4094711751257690,"authorId":4094711751257690,"authorIdStr":"4094711751257690","name":"不油腻的哒哒哒","avatar":"https://static.tigerbbs.com/521e89acc5ee91cd53fceb36809286c3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>failure is the mother of success</p></body></html>","htmlText":"<html><head></head><body><p>failure is the mother of success</p></body></html>","text":"failure is the mother of success","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/619521606","repostId":2225263513,"repostType":2,"repost":{"id":"2225263513","pubTimestamp":1649338269,"share":"https://www.laohu8.com/m/news/2225263513?lang=&edition=full","pubTime":"2022-04-07 21:31","market":"us","language":"en","title":"Aptinyx slides as diabetic pain trial fails to reach main goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2225263513","media":"seekingalpha","summary":"syahrir maulana/iStock via Getty Images   The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX","content":"<html><body><p><figure> <picture> <img src=\"https://media.gettyimages.com/photos/diabetic-neuropathy-text-on-sticky-notes-with-office-desk-concept-picture-id1282091481?b=1&amp;k=20&amp;m=1282091481&amp;s=170667a&amp;w=0&amp;h=8-hdaA47vKiB4O_09z6qoNYLdrVgKkkqD5K6qw9J5jA=\"/> </picture> <figcaption><p>syahrir maulana/iStock via Getty Images</p></figcaption> </figure></p> <ul> <li>The shares of clinical-stage biotech, Aptinyx (<span>NASDAQ:APTX</span>) have <span>lost ~53%</span> in the<span> pre-market Thursday after the company announced that its Phase 2b clinical study for NYX-2925 did not reach the primary endpoint in patients with painful diabetic peripheral neuropathy (DPN).</span> </li> <li>The 229-patient randomized, double-blind study did not demonstrate a statistically significant separation from placebo in terms of its primary endpoint, which was the change in pain from baseline measured over 12 weeks using a rating scale, the company said.</li> <li>“We are clearly disappointed that the study did not meet its primary endpoint,” Chief Executive Andy Kidd remarked, adding, “unfortunately, the data from this study do not currently point to a path forward in development for painful DPN.”</li> <li>However, the experimental therapy was well tolerated in the trial with no “concerning safety issues.” according to Aptinyx (APTX).</li> <li>NYX-2925 is currently undergoing a Phase 2b study for fibromyalgia, with data expected in mid-3Q 2022, the company said. </li> </ul></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptinyx slides as diabetic pain trial fails to reach main goal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptinyx slides as diabetic pain trial fails to reach main goal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-07 21:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3821627-aptx-stock-slides-as-diabetic-pain-trial-fails-to-reach-main-goal><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>syahrir maulana/iStock via Getty Images   The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX) have lost ~53% in the pre-market Thursday after the company announced that its Phase 2b clinical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3821627-aptx-stock-slides-as-diabetic-pain-trial-fails-to-reach-main-goal\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"APTX":"Aptinyx Inc.","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3821627-aptx-stock-slides-as-diabetic-pain-trial-fails-to-reach-main-goal","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2225263513","content_text":"syahrir maulana/iStock via Getty Images   The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX) have lost ~53% in the pre-market Thursday after the company announced that its Phase 2b clinical study for NYX-2925 did not reach the primary endpoint in patients with painful diabetic peripheral neuropathy (DPN).  The 229-patient randomized, double-blind study did not demonstrate a statistically significant separation from placebo in terms of its primary endpoint, which was the change in pain from baseline measured over 12 weeks using a rating scale, the company said. “We are clearly disappointed that the study did not meet its primary endpoint,” Chief Executive Andy Kidd remarked, adding, “unfortunately, the data from this study do not currently point to a path forward in development for painful DPN.” However, the experimental therapy was well tolerated in the trial with no “concerning safety issues.” according to Aptinyx (APTX). NYX-2925 is currently undergoing a Phase 2b study for fibromyalgia, with data expected in mid-3Q 2022, the company said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":368,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}